PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases

PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Controlled Release - Volume 168, Issue 2, 10 June 2013, Pages 200-208

Lisa M. Kaminskas, David B. Ascher, Victoria M. McLeod, Marco J. Herold, Caroline P. Le, Erica K. Sloan, Christopher J.H. Porter,